MedPath

Study of Growing Biofilm by an Antiplaque Mouthrinse

Phase 3
Completed
Conditions
Dental Plaque
Interventions
Drug: mouthrinse (Grape Seed Extract + nicomethanol fluorhydrate)
Other: mouthrinse containing non-active component
Registration Number
NCT00838266
Lead Sponsor
University Hospital, Bordeaux
Brief Summary

The objective of this study is to evaluate the efficiency of a new mouthrinse on dental plaque deposits.

The study is carried out on 50 volunteers that are asked to use the mouthrinse without any other oral hygiene measure, during 4 days. It is a double bind, cross-over, randomized design: the same subjects test the active product and the placebo.

Detailed Description

The prevention of oral diseases is mainly targeted at the control of dental plaque. While tooth brushing is an effective method to remove plaque mechanically, it is not always sufficient and chemical antiplaque agents could be helpful. Some of them are used for their antibacterial action, the gold standard being chlorhexidine. Despite the great benefit of this bactericidal approach, the search continues for active ingredients that could prevent dental plaque formation without affecting the biological equilibrium within the oral cavity.

The aim of this study is to evaluate the efficiency of a mouthrinse, containing red grape seed extract and nicométhanol fluorhydrate, in the control of dental plaque deposit in a 4-days plaque regrowth model.

The study is a double blind randomized cross-over design, involving 50 healthy volunteers. During the treatment periods (4 days) no oral hygiene, measures excepting rinsing with the allocated product (active/non active) are permitted.

On day 1, the subjects receive professional prophylaxis. The mouthrinse is used pure, three times per day, after each meal. On day 5, subjects will be scored for disclosed plaque using the Quigley Hein index (modified by Turesky).

After a 2 weeks wash-out period, the subject receives the other product (active/non active) and uses it as in the first period.

On day 5, subjects will be scored again for disclosed plaque

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
50
Inclusion Criteria
  • Healthy volunteer
  • without caries
  • with at least 20 natural teeth excluding third molars
  • Women using contraceptives for at least twelve weeks and while on study
  • Protected by French social security system
  • Written informed consent
Exclusion Criteria
  • Pregnancy or breast feeding
  • Volunteers with partial denture or orthodontic appliance
  • Person protected by the law who
  • Person unable to give their consent to participate to the study.
  • Under aged
  • Current participation in another clinical trial
  • Oral pathologies
  • Systemic diseases
  • Volunteers allergic to of the componentst of the tested products
  • Volunteers with hyposalivation or xerostomia
  • Treatment with antibiotics o intestinal antiseptics within 3 month before inclusion
  • Treatment with oral antiseptics within 1 month before inclusion
  • Alcoholic consumption more than 20 g/day (or 2 glasses)
  • Heavy smokers
  • Volunteers drinking a lot of tea or coffee

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
1mouthrinse (Grape Seed Extract + nicomethanol fluorhydrate)Antiplaque mouthrinse containing active component (Grape Seed Extract + nicométhanol fluorhydrate)
2mouthrinse containing non-active componentAntiplaque mouthrinse containing non-active component
Primary Outcome Measures
NameTimeMethod
Plaque index of Quickley-Hein modified by Tureski. Plaque deposits are scored on all natural teeth (except third molars) after staining.Measures are done on days 5 of the two plaque growth periods
Secondary Outcome Measures
NameTimeMethod
Product toleranceon days 5 of the two plaque growth periods
Product acceptability (oral sensation)on days 5 of the two plaque growth periods

Trial Locations

Locations (1)

CHU de Bordeaux - Hôpital ST André - 1 rue Jean Burguet

🇫🇷

Bordeaux, France

© Copyright 2025. All Rights Reserved by MedPath